-
Beyond Jadad: some essential features in trial quality
Sunny Y Alperson ,Vance W Berger
Perspective: Clinical Investigation
-
Beyond Jadad: some essential features in trial quality
Sunny Y Alperson ,Vance W Berger
Perspective: Clinical Investigation
-
Beyond Jadad: some essential features in trial quality
Sunny Y Alperson ,Vance W Berger
Perspective: Clinical Investigation
-
Beyond Jadad: some essential features in trial quality
Sunny Y Alperson ,Vance W Berger
Perspective: Clinical Investigation
-
Beyond Jadad: some essential features in trial quality
Sunny Y Alperson ,Vance W Berger
Perspective: Clinical Investigation
-
Beyond Jadad: some essential features in trial quality
Sunny Y Alperson ,Vance W Berger
Perspective: Clinical Investigation
-
Beyond Jadad: some essential features in trial quality
Sunny Y Alperson ,Vance W Berger
Perspective: Clinical Investigation
-
Beyond Jadad: some essential features in trial quality
Sunny Y Alperson ,Vance W Berger
Perspective: Clinical Investigation
-
Novel immunotherapeutic agents for castration-resistant prostate cancer: update from clinical trials
Nishith Singh, Ravi Madan, James L Gulley
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel immunotherapeutic agents for castration-resistant prostate cancer: update from clinical trials
Nishith Singh, Ravi Madan, James L Gulley
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel immunotherapeutic agents for castration-resistant prostate cancer: update from clinical trials
Nishith Singh, Ravi Madan, James L Gulley
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel immunotherapeutic agents for castration-resistant prostate cancer: update from clinical trials
Nishith Singh, Ravi Madan, James L Gulley
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel immunotherapeutic agents for castration-resistant prostate cancer: update from clinical trials
Nishith Singh, Ravi Madan, James L Gulley
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel immunotherapeutic agents for castration-resistant prostate cancer: update from clinical trials
Nishith Singh, Ravi Madan, James L Gulley
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel immunotherapeutic agents for castration-resistant prostate cancer: update from clinical trials
Nishith Singh, Ravi Madan, James L Gulley
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel immunotherapeutic agents for castration-resistant prostate cancer: update from clinical trials
Nishith Singh, Ravi Madan, James L Gulley
Review: Clinical Trail Outcomes: Clinical Investigation
-
Evolving trial design in secondary progressive multiple sclerosis
Jeremy Chataway ,Susan Todd
Editorial: Clinical Investigation
-
Evolving trial design in secondary progressive multiple sclerosis
Jeremy Chataway ,Susan Todd
Editorial: Clinical Investigation
-
Evolving trial design in secondary progressive multiple sclerosis
Jeremy Chataway ,Susan Todd
Editorial: Clinical Investigation
-
Evolving trial design in secondary progressive multiple sclerosis
Jeremy Chataway ,Susan Todd
Editorial: Clinical Investigation
-
Evolving trial design in secondary progressive multiple sclerosis
Jeremy Chataway ,Susan Todd
Editorial: Clinical Investigation
-
Evolving trial design in secondary progressive multiple sclerosis
Jeremy Chataway ,Susan Todd
Editorial: Clinical Investigation
-
Evolving trial design in secondary progressive multiple sclerosis
Jeremy Chataway ,Susan Todd
Editorial: Clinical Investigation
-
Evolving trial design in secondary progressive multiple sclerosis
Jeremy Chataway ,Susan Todd
Editorial: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, Iss 6
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, Iss 6
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, Iss 6
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, Iss 6
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, Iss 6
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, Iss 6
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, Iss 6
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, Iss 6
Acknowledgements: Clinical Investigation
-
Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data
Brendan Boyce, Lianping Xing
Review Article: Clinical Investigation
-
Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data
Brendan Boyce, Lianping Xing
Review Article: Clinical Investigation
-
Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data
Brendan Boyce, Lianping Xing
Review Article: Clinical Investigation
-
Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data
Brendan Boyce, Lianping Xing
Review Article: Clinical Investigation
-
Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data
Brendan Boyce, Lianping Xing
Review Article: Clinical Investigation
-
Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data
Brendan Boyce, Lianping Xing
Review Article: Clinical Investigation
-
Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data
Brendan Boyce, Lianping Xing
Review Article: Clinical Investigation
-
Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data
Brendan Boyce, Lianping Xing
Review Article: Clinical Investigation
-
Lacosamide as a new add-on therapy for the treatment of partial-onset seizures
Steve S Chung
Review Article: Clinical Investigation
-
Lacosamide as a new add-on therapy for the treatment of partial-onset seizures
Steve S Chung
Review Article: Clinical Investigation
-
Lacosamide as a new add-on therapy for the treatment of partial-onset seizures
Steve S Chung
Review Article: Clinical Investigation
-
Lacosamide as a new add-on therapy for the treatment of partial-onset seizures
Steve S Chung
Review Article: Clinical Investigation
-
Lacosamide as a new add-on therapy for the treatment of partial-onset seizures
Steve S Chung
Review Article: Clinical Investigation
-
Lacosamide as a new add-on therapy for the treatment of partial-onset seizures
Steve S Chung
Review Article: Clinical Investigation
-
Lacosamide as a new add-on therapy for the treatment of partial-onset seizures
Steve S Chung
Review Article: Clinical Investigation
-
Lacosamide as a new add-on therapy for the treatment of partial-onset seizures
Steve S Chung
Review Article: Clinical Investigation